Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies Meeting Abstract


Authors: Tse, A.; Yazji, S.; Naing, A.; Matthews, D.; Schwartz, G.; Lawhorn, K.; Kurzrock, R.
Abstract Title: Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies
Meeting Title: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Journal Title: EJC Supplements
Volume: 6
Issue: 12
Meeting Dates: 2008 Oct 21-24
Meeting Location: Geneva, Switzerland
ISSN: 1359-6349
Publisher: Pergamon-Elsevier Science Ltd  
Date Published: 2008-10-01
Start Page: 124
Language: English
ACCESSION: WOS:000261221200394
DOI: 10.1016/s1359-6349(08)72329-2
PROVIDER: wos
Notes: --- - Meeting Abstract: 395 - Poster - 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - OCT 21-24, 2008 - Geneva, SWITZERLAND - "Source: Wos"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gary Schwartz
    385 Schwartz
  2. Archie Tse
    34 Tse